Shanu Modi

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

60h-index19.2kcitations416works6.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(201), Cancer Treatment and Pharmacology(108), Advanced Breast Cancer Therapies(94), Monoclonal and Polyclonal Antibodies Research(72), Breast Cancer Treatment Studies(58)

Publications415 total

Abstract PS2-09-03: Th1-biased cytokine signatures as biomarkers of clinical benefit following SV-BR-1-GM cancer vaccination in breast cancer
Clinical Cancer Research·2026
Upadacitinib for patients with eosinophilic esophagitis refractory to dupilumab
Allergology International·2025Open Access
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies
The Oncologist·2025· 1 citedOpen Access
Evaluating post-T-DXd treatment strategies in HER2-positive metastatic breast cancer
Breast Cancer Research and Treatment·2025Open Access
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
Annals of Oncology·2025· 1 cited
Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding
Cancer Discovery·2025· 5 citedOpen Access
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
Annals of Oncology·2025· 17 citedOpen Access
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial
Nature Medicine·2025· 7 citedOpen Access
Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis
Annals of Oncology·2025· 5 citedOpen Access
Step‐Down Dupilumab Dosing Regimen in Patients With Eosinophilic Esophagitis: A Real‐World, Retrospective Study
Clinical & Experimental Allergy·2025Open Access
Abstract GS3-09: Multimodal integration of real world clinical and genomic data for the prediction of CDK4/6 inhibitors outcomes in patients with HR+/HER2- metastatic breast cancer
Clinical Cancer Research·2025· 2 cited
Abstract P5-03-09: Evaluating Post-T-DXd Treatment Strategies in HER2-positive Metastatic Breast Cancer
Clinical Cancer Research·2025
Abstract P3-08-24: Valemetostat and Trastuzumab Deruxtecan in Patients With HER2-Low, Previously Treated, Unresectable or Metastatic Breast Cancer
Clinical Cancer Research·2025
Abstract P5-03-15: EmpowHER 303: A phase 3 study to evaluate the efficacy and safety of zanidatamab vs trastuzumab with chemotherapy in patients (pts) with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, trastuzumab deruxtecan
Clinical Cancer Research·2025
Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challenges
Journal of Neuro-Oncology·2025
Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy
JACC CardioOncology·2025· 7 citedOpen Access
Effect of ERBB2 activating mutations on enhanced internalization and activity of trastuzumab deruxtecan in HER2-non-amplified metastatic breast cancer.
Journal of Clinical Oncology·2025· 2 cited
Comparative meta-analysis of cisplatin dosing schedules in definitive chemoradiotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Journal of Clinical Oncology·2025
Cardiovascular implications of metabolic dysfunction-associated fatty liver disease and type 2 diabetes mellitus: A meta-analysis
World Journal of Hepatology·2025· 4 citedOpen Access
Sequential Antibody-Drug Conjugate Therapy in Patients With Metastatic Breast Cancer Treated With Sacituzumab Govitecan and Trastuzumab Deruxtecan
JCO Precision Oncology·2025· 3 cited
page 1 of 21Next →

Frequent Co-authors

Clifford A. Hudis(15), Ian E. Krop(13), Sarat Chandarlapaty(11), Larry Norton(11), Junji Tsurutani(7), Kenji Tamura(6), Hiroji Iwata(6), Maura N. Dickler(6), Gabriella D’Andrea(6), Sujata Patil(6), Javad Shahidi(5), Chau T. Dang(5), Mark E. Robson(5), Jorge S. Reis‐Filho(5), David B. Solit(5), Shunji Takahashi(5), Komal Jhaveri(5), Mary Ellen Moynahan(5), Eric P. Winer(5), Andrew D. Seidman(5)